Skip to main content

Table 4 Randomized placebo-controlled trials with oral glycoprotein IIb/IIIa inhibitors

From: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Trial (number of patients) Agent tested Indications Entry criteria Primary endpoints
EXCITE (7232) Xemilofiban PCI Patients with angiographic evidence of Death, MI, and recurrent revascularization,
    significant CAD requiring PCI at 30 and 182 days
OPUS-TIMI 16 Orofiban ACS Unstable coronary syndromes; Q-wave Death, MI, and recurrent ischemia,
(10,302)    MI, non-Q-wave MI, and UA, in preceding revascularization, or stroke, at 30 days and
    72 hours with either ECG changes, 6 months
    enzyme elevation, or prior CAD  
SYMPHONY (9233) Sibrafiban ACS ACS event after stabilization Death, MI, and severe recurrent ischemia,
     at 90 days
SECONDSYMPHONY Sibrafiban ACS ACS event after stabilization Death, MI, and severe recurrent ischemia,
(6671)     at 90 days
BRAVO (9200) Lotrafiban ACS + CVA Recent MI, UA, TIA or stroke, or PVD Death, stroke, recurrent ischemia, or
     revascularization, at 6 months-2 years
     (stopped prematurely)
  1. ACS, Acute coronary syndromes; CAD, coronary artery disease; CVA, cerebrovascular accident; ECG, electrocardiogram; MI, myocardial infarction; PCI, percutaneous coronary interventions; PVD, peripheral vascular disease; TIA, transient ischemic attack; UA, unstable angina.